3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
4
Unknown
2
Withdrawn
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Mouth Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Sentinel Lymph Node Biopsy (SLNB)
1
Recurrence
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lymphatic Metastasis
1
Endometrial Neoplasms
1
Eccrine Porocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Interventions
pembrolizumab
54
Nivolumab
50
Ipilimumab
28
Cyclophosphamide
16
binimetinib
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
fludarabine
9
Radiosurgery
9
relatlimab
8
encorafenib
8
Opdualag
8
Biopsy
8
aldesleukin
7
Interleukin-2
7
atezolizumab
6
Immunotherapy
6
Blood Specimen Collection
6
cemiplimab
5
CTLA-4 Antigen
5
Bevacizumab
5
trametinib
4
fludarabine phosphate
4
dabrafenib
4
Temozolomide
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
spartalizumab
3
Surgical Procedures, Operative
3
Metformin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Melanoma
×
Sentinel Lymph Node Biopsy
×
Clear all
NCT06666634
2024-10-30
NANOSCAN
The Netherlands Cancer Institute
Phase NA
Recruiting
29 enrolled